Although chimeric antigen receptor T-cell (CAR-T) therapy produces a high complete
remission rate among patients with relapsed/refractory B-cell acute lymphoblastic leukemia …

Anti‐thymocyte globulin (ATG) or post‐transplant cyclophosphamide (PTCy)‐based
regimens are widely used for graft‐versus‐host disease (GVHD) prophylaxis in …

Hematopoietic stem cell transplantation from a haploidentical donor is increasingly used
and has become a standard donor option for patients lacking an appropriately matched …

Background For patients with steroid-refractory acute graft-versus-host disease (SR-
aGVHD), effective second-line regimens are urgently needed. Mesenchymal stromal cells …

Poor graft function (PGF) and prolonged isolated thrombocytopenia (PT) remain life-
threatening complications after allogeneic hematopoietic stem cell transplantation (allo …

Acute graft‐vs‐host disease (aGVHD) is one of the most important causes of early mortality
after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), particularly for those …

Background Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of
haploidentical donor (HID) transplant for refractory acute leukemia need to be further …

Granulocyte colony-stimulating factor (G-CSF), a growth factor for neutrophils, has been
successfully used for stem cell mobilization and T cell immune tolerance induction. The …

Haploidentical donor stem cell transplantation (haplo-SCT) has made great advances in
recent decades. The granulocyte colony-stimulating factor (G-CSF)-and antithymocyte …

The present review describes the biology of human leukocyte antigen haplotype
mismatched (“haploidentical”) transplantation, its translation to clinical practice to cure …